A study published today in The BMJ found that patients who received the anti-clotting medication rivaroxaban for 12 weeks as opposed to the usual 6 weeks after a blood clot in the lower leg had a lower risk of developing additional clots up to two years after treatment.
In addition, there was no increased risk of bleeding during the additional six weeks of treatment, a common side effect of anti-clotting medications.
Rivaroxaban is a blood thinner. It helps blood clot (thicken) more slowly, and doctors administer rivaroxaban to patients with life-harming blood clots. It is available from any rivaroxaban manufacturer with dosage details.
In patients who have already had a blood clot in their leg, including those who have isolated distal deep vein thrombosis (DVT), anticoagulation prevents the formation of additional clots. However, doctors are still unsure whether or not anticoagulation should be administered to all patients with distal DVT and for how long.
Although isolated distal deep vein thrombosis (DVT) is less dangerous than proximal DVT, it can still result in pulmonary embolism in up to 22% of patients who do not receive treatment. Doctors recommend anticoagulant therapy for patients with symptoms or risk factors who have isolated DVT.
402 adult participants volunteered for the study to test rivaroxaban treatment. Participants were randomly assigned to receive rivaroxaban 20 mg or a placebo once daily for an additional six weeks after receiving the standard dose for the first six weeks of the study. There was a follow-up for 24 months.
The patients with clotting and bleeding complications received 20 mg of rivaroxaban. When the dose of placebo once daily wasn’t effective, for an additional six weeks after receiving a standard dose of rivaroxaban for six weeks was also administered, according to a study of pharma contract manufacturers in India.
A repetitive study at three weeks, six weeks, three months, and twenty-four months was a checkup for new clots or heavy bleeding. Preventing recurrent DVT was responsible for the majority of this reduction. During the two-year study, there were no major bleeding incidents, and the researchers estimated that rivaroxaban avoids one blood clot for every 13 patients.
During the two-year study, no major bleeding occurred, and the researchers estimate that every 13 patients can avoid one blood clot by receiving additional rivaroxaban.
Due to slow enrollment and the onset of the COVID-19 pandemic, the researchers couldn’t reach the ideal sample size of over 1,000 patients. However, the results were consistent among patients with other types of clots, such as those in the upper arm, and this was a well-designed trial, indicating that the findings are robust.
“Rivaroxaban administered for three months effectively and safely reduces the risk of recurrent venous thromboembolism compared with rivaroxaban administered for six weeks in patients with isolated distal DVT.”
Pharma contract manufacturers in India are experiencing a boom in business because of studies demonstrating that rivaroxaban is a drug that reduces blood clot risks after distal DVT.
The studies may produce positive outcomes if they have more supporting data. Clinics are always looking for a reputable rivaroxaban manufacturer. Pinnacle is a top oncology pharma company in India that brings innovation and experience.
Source- Ageno W, Bertù L, Bucherini E, Camporese G, Dentali F, Iotti M, Lessiani G, Parisi R, Prandoni P, Sartori M, Visonà A, Bigagli E, Palareti G, on behalf of the RIDTS study group. (2022) “Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomized controlled trial.” The BMJ
